Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:21 AM
Ignite Modification Date:
2025-12-25 @ 12:21 AM
NCT ID:
NCT03974958
Eligibility Criteria:
Inclusion Criteria:
• Case AAA T3 : Patients included in the ACTA study. They benefited from aortic imaging assessment at times T1 and T2 and were not operated on AAA.
• AOMI Case Control : Patients referred for hospitalization or referred to vascular surgery for management of chronic peripheral claudication on AOMI not associated with aneuric aneurysm evolutionary or previously operated. They must benefit from a CT angiography of the aorta and lower extremity arteries as well as a cardiac ultrasound scan.
Exclusion Criteria:
* minor patients;
* pregnant women;
* patients with cancer at the time of inclusion;
* contraindication to iodinated contrast medium: allergy to iodine, severe renal insufficiency (≤40 ml / min);
* patients presenting one of the following pathologies associated with a disruption of the activation of coagulation and / or inflammation (less than 6 weeks old):
* Arterial thrombotic disease: acute coronary syndrome, TIA/CVD, peripheral artery acute ischemia and/or anti-vitamin K (AVK) treatment;
* venous thrombotic pathology: peripheral venous thrombosis of less than 3 months and/or under AVK treatment, pulmonary embolism less than 6 months old and/or under AVK treatment;
* surgery;
* revascularization with angioplasty;
* critical ischemia patente;
* permanent atrial fibrillation due to associated microparticle elevation, and AVK treatment;
* major haemorrhage;
* acute infection.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT03974958
Study Brief:
Protocol Section:
NCT03974958